AzTrials
AzTrials

Bone Marrow EdemaNCT03941977

Treatment of Bone Marrow Edema Lesions of the Knee With Percutaneous Grafting

A study testing Percutaneous introduction of cannula, Magnetic resonance imaging and Bone Grafting in people with Bone Marrow Edema, run by University of Sao Paulo General Hospital at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Objective 1. To evaluate the technique of percutaneous grafting with bone substitute in the knee as to its applicability and technical feasibility. 2. Evaluate the results regarding functional improvement and prevention of the evolution of joint cartilage degeneration. Read more about this study

Who is it for?
Ages 40 to 85 years
Conditions the study is for
Bone Marrow Edema
What is being tested?
Percutaneous introduction of cannula, Magnetic resonance imaging and Bone Grafting
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteBrazil
Study dates
5 Nov 2014to 30 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 40 to 85 years
  • Gender: both genders
  • Knee pain for at least 6 months
  • Hypercaption lesion in subchondral region of tibial plateau or femoral condyle in T2-weighted magnetic resonance imaging with fat suppression.

Who cannot join

  • Rheumatologic diseases diagnosed in treatment
  • Renal insufficiency requiring hemodialysis
  • Not ambulatory
  • Knee osteoarthrosis with Kellegren / Lawrence classification greater than 3
  • Alignment in varus or valgus greater than 8 degrees in relation to the mechanical axis
  • Radiographic changes in the femoro-patellar joint associated with symptoms of anterior knee pain

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Hospital das Clinicas - University of Sao Paulo

    São Paulo, 05403-010

Other trials in Brazil

About this study

Objective

  1. To evaluate the technique of percutaneous grafting with bone substitute in the knee as to its applicability and technical feasibility.
  2. Evaluate the results regarding functional improvement and prevention of the evolution of joint cartilage degeneration.
Read more

Material and methods Twenty patients from the Knee Group clinic who meet the criteria will be selected.

Magnetic resonance imaging will be analyzed on the PACS server. Through the resonance will be performed evaluation of the size of the bone edema in volume and its proportion in relation to the size of the affected condyle or tibial plateau and the cartilage of the femoro-tibial joint. The lesions will then be mapped in the coronal and sagittal plane.

Radiographs will be taken in antero-posterior, profile, Rosenberg knee and lower limb views.

Evaluation of the patients will be performed by the visual analog pain scale and by the KOOS, IKDC and SF-36v1 indices.

Description of Surgical Technique After the mapping the patient will be submitted to the procedure. The procedure consists in the application of a bone substitute based on injectable calcium phosphate in the area of bone edema previously mapped with the aid of radioscopy to guide. After confirming the proper positioning of the guidewire, a trephine is introduced through which the product will be injected. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.

The procedures will be performed in a surgical center, with conventional antisepsis and asepsis techniques and under spinal anesthesia. The patient will be hospitalized and must be discharged on the first postoperative day. After the procedure the patients will be under partial load as tolerated for two weeks with free range of motion and will start physiotherapy after 2 weeks of the procedure. During hospitalization the patient will receive analgesia with intravenous Dipirone 1g every 6 hours associated with Tramadol 100mg intravenously every 8 hours if severe pain. After discharge the patient will receive analgesia with dipyrone 1g orally every 6 hours associated with Tramadol 100mg orally every 8 hours if severe pain, and Tramadol used by the patient was quantified.

Patients will then be re-evaluated at 1, 3, 12, 24 and 48 weeks with the same previous criteria and at 12 months new MRI with the same previous protocol will be performed.

Read the detailed description

Initial assessment

All the patients included in the study were submitted to the initial evaluation, in which the following exams and scales were performed:

  • Magnetic resonance of the affected knee, according to IOTHCFMUSP standard radiology protocol;
  • Panoramic radiography of lower limbs to measure limb alignment;
  • X-ray in antero-posterior incidence with load and knee profile;
  • Functional ranges of subjective IKDC, KOOS and SF-36v1;
  • Analog visual pain scale.

Radiographic evaluation and magnetic resonance imaging

The radiographs were evaluated and classified by a specialist radiologist in musculoskeletal, according to the Kellgren-Lawrence classification. The radiographs were not identified as to the moment of accomplishment, before or after the procedure. However, in many cases it was possible to identify signs of the procedure in the image, making the evaluator blind.

In the MRI images, the location of the bone edema was evaluated in relation to the affected bone (femur or tibia) and affected compartment (medial or lateral). The extent of edema divided into three levels according to the percentage of affected area of the coronal section of the femoral condyle or tibial plateau was also evaluated, with grade 1 being less than 25%, grade 2 between 25% and 50%, and grade 3 greater than 75 %. In the subchondral bone was also recorded the presence of fracture line, cysts and impactions / collapses of the articular surface. In the presence of impaction this was measured in millimeters.

Clinical and functional evaluation

The patients were evaluated by the functional scales: KOOS and subjective IKDC. Quality of life was also assessed by the SF-36v1 questionnaire.

Patient follow-up

Patients were followed in outpatient clinics at 1, 3, 6, 12, 24 and 48 weeks after the surgical procedure. Functional scales were repeated in all consultations. The quality of life scale was repeated at 24 and 48 weeks. Radiographs and MRI were repeated after 48 weeks of surgery.

Description of surgical technique

Magnetic resonance imaging of the patients was mapped in the surgical center to define the area of the lesion, as well as planning of the injection site at the center of the lesion, trajectory and cannula entry point. The cannula trajectory was defined by prioritizing an appropriate angle of attack for the entry point and larger distances of intraosseous trajectory, in order to avoid extravasation of the bone substitute through the cannula inlet.

The procedures were performed under spinal anesthesia, in a surgical center. The patients were placed in dorsal decubitus on a radiolucent table, with a cushion below the ipsilateral hip, for better control of the external rotation of the limb and a cushion also under the ipsilateral knee, aiding in the lateral incidence of fluoroscopy, avoiding the overlap of the knee image contralateral.

The material for the procedure was:

  • An 8G metal cannula with distal and lateral exit orifice at the tip
  • Metal cannula of the cannula with introductory tip with cut
  • Metal cannula embolus with blunt tip
  • High Flow Disposable Three-Way Infusion Faucet
  • Five 1mL syringes with thread at the tip
  • One syringe to prepare the Graftys HBS® bone substitute

According to preoperative planning, with the help of fluoroscopy in front and profile incidences, the cannula entry point was demarcated, with the placement of the cannula on the skin. Incisions of 5 mm in length were performed with a n11 scalpel blade at the point of entry into the skin. The cannulae were introduced, with fluoroscopy control, towards the center of the previously determined lesion. The progression was done manually or with the aid of hammer, when greater resistance was found.

During the introduction of the cannula, oblique incidences of fluoroscopy were performed to avoid perforation of the opposing cortex. The introduction of the cannula was performed very carefully when approaching the opposite cortical, with the possibility of using the blunt tip for cannula, making it difficult to perforation of the cortical.

The bone substitute was then prepared by mixing the solid content with the liquid to liquid / pasty state and transferred to 1 ml syringes. Transfer to smaller diameter syringes is important to achieve an injection flow with lower pressure application. The bone substitutes when subjected to higher pressures pass into a separation phase in which the liquid separates from the solid part, making it impossible to deliver the material in the desired area.

The 1 ml syringes were connected to the cannulae already positioned at the site determined for filling. The bone substitute was injected, interleaving the passage of a metal plunger through the cannula, between each syringe. Through the fluoroscopy it was possible to visualize the distribution of the product in the bone marrow, ensuring that the application was according to the mapping of the lesion and controlling the presence of possible extravasations. The amount of product injected was defined by the control of filling the area of the lesion by fluoroscopy. In cases of intra-articular extravasation, the injection was interrupted. After the injection was completed, it was waited 5 minutes before removal of the cannula, to reduce the reflux of the material through the inlet.

Post-operative care

The patients were hospitalized until the day after the procedure. Full load was allowed as tolerated for two weeks, with free range of motion. During hospitalization, patients received analgesia with intravenous dipyrone 1g every 6 hours, associated with intravenous tramadol 100mg every 8 hours if they presented severe pain greater than 7. After discharge, patients received analgesia with dipyrone 1g orally 6 in 6 hours, associated with tramadol 100mg orally every 8 hours, if severe pain, for a week, and the tramadol used by the patient in this period was quantified.

Surgical incision stitches were removed at the first outpatient appointment 1 week after surgery. The patients did not undergo physiotherapy or any type of rehabilitation after the procedure.

Being tested
Percutaneous introduction of cannula, Magnetic resonance imaging, Bone Grafting

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Percutaneous introduction of cannulaDevice

    Also called Arm: Experimental: Surgery

    An 8 gauge cannula is introduced at the site of the bone marrow lesion. The introduction of the cannula is guided by fluoroscopy.

  • Magnetic resonance imagingDiagnostic test

    Also called Arm: Experimental: Surgery

    MRI scans will be performed on a 1.5 T (Signa Excite HD, GE Healthcare, Waukesha, WI, USA) and a specific knee coil (HD TRKnee 8 Ch High Resolution Knee Array) will be used.

  • Bone GraftingBiological

    A bone substitute consisting of calcium phosphate will be injected through the cannula, previously inserted, filling the area of the bone marrow lesion. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.

Study groups in NCT03941977
Study groupRoleWhat they receive
SurgeryExperimentalGroup evaluated with MRI and submitted to the percutaneous introduction of cannula for bone grafting
Receives: Device: Percutaneous introduction of cannula; Diagnostic Test: Magnetic resonance imaging; Biological: Bone Grafting

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Knee injury and Osteoarthritis Outcome Score

    Evatualion of Pain, other Symptoms, Function in daily living, Function in sport and recreation and knee related Quality of life

    Measured: Pre-operative

  2. Knee injury and Osteoarthritis Outcome Score

    Evatualion of Pain, other Symptoms, Function in daily living, Function in sport and recreation and knee related Quality of life, comparative with pre-optative evaluation

    Measured: 1 week postoperative

  3. Knee injury and Osteoarthritis Outcome Score

    Evatualion of Pain, other Symptoms, Function in daily living, Function in sport and recreation and knee related Quality of life, comparative with pre-optative evaluation

    Measured: 3 weeks postoperative

  4. Knee injury and Osteoarthritis Outcome Score

    Evatualion of Pain, other Symptoms, Function in daily living, Function in sport and recreation and knee related Quality of life, comparative with pre-optative evaluation

    Measured: 6 weeks postoperative

  5. Knee injury and Osteoarthritis Outcome Score

    Evatualion of Pain, other Symptoms, Function in daily living, Function in sport and recreation and knee related Quality of life, comparative with pre-optative evaluation

    Measured: 12 weeks postoperative

  6. Knee injury and Osteoarthritis Outcome Score

    Evatualion of Pain, other Symptoms, Function in daily living, Function in sport and recreation and knee related Quality of life, comparative with pre-optative evaluation

    Measured: 24 weeks postoperative

  7. Knee injury and Osteoarthritis Outcome Score

    Evatualion of Pain, other Symptoms, Function in daily living, Function in sport and recreation and knee related Quality of life, comparative with pre-optative evaluation

    Measured: 48 weeks postoperative

  8. International Knee Documentation Committee

    knee-specific patient-reported outcome measure

    Measured: Pre-operative

  9. International Knee Documentation Committee

    knee-specific patient-reported outcome measure, comparative with pre-optative evaluation

    Measured: 1 week postoperative

  10. International Knee Documentation Committee

    knee-specific patient-reported outcome measure, comparative with pre-optative evaluation

    Measured: 3 weeks postoperative

  11. International Knee Documentation Committee

    knee-specific patient-reported outcome measure comparative with pre-optative evaluation

    Measured: 6 weeks postoperative

  12. International Knee Documentation Committee

    knee-specific patient-reported outcome measure, comparative with pre-optative evaluation

    Measured: 12 weeks postoperative

  13. International Knee Documentation Committee

    knee-specific patient-reported outcome measure, comparative with pre-optative evaluation

    Measured: 24 weeks postoperative

  14. International Knee Documentation Committee

    knee-specific patient-reported outcome measure, comparative with pre-optative evaluation

    Measured: 48 weeks postoperative

  15. Short Form 36 Health Survey

    Patient-reported survey of patient health

    Measured: Pre-operative

  16. Short Form 36 Health Survey

    Patient-reported survey of patient health, comparative with pre-optative evaluation

    Measured: 24 weeks postoperative

  17. Short Form 36 Health Survey

    Patient-reported survey of patient health, comparative with pre-optative evaluation

    Measured: 48 weeks postoperative

  18. Visual analog scale for Pain

    Unidimensional measure of pain intensity

    Measured: Pre-operative

  19. Visual analog scale for Pain

    Unidimensional measure of pain intensity, comparative with pre-optative evaluation

    Measured: 1 Week postoperative

  20. Visual analog scale for Pain

    Unidimensional measure of pain intensity, comparative with pre-optative evaluation

    Measured: 3 weeks postoperative

  21. Visual analog scale for Pain

    Unidimensional measure of pain intensity, comparative with pre-optative evaluation

    Measured: 6 weeks postoperative

  22. Visual analog scale for Pain

    Unidimensional measure of pain intensity, comparative with pre-optative evaluation

    Measured: 12 weeks postoperative

  23. Visual analog scale for Pain

    Unidimensional measure of pain intensity, comparative with pre-optative evaluation

    Measured: 24 weeks postoperative

  24. Visual analog scale for Pain

    Unidimensional measure of pain intensity, comparative with pre-optative evaluation

    Measured: 48 weeks postoperative

Secondary outcomes (1)
  1. Edema Volume evaluation

    MRI evaluation

    Measured: 1 year postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2019
  2. Study start5 Nov 2014
  3. Primary completion30 Dec 2018
  4. Study completion30 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03941977
Sponsor's protocol ID
37392614.9.0000.0068
Status last verified
Apr 2019
First submitted
20 Feb 2017
Last updated
20 May 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Percutaneous introduction of cannula, Magnetic resonance imaging and Bone Grafting in people with Bone Marrow Edema, run by University of Sao Paulo General Hospital at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Knee injury and Osteoarthritis Outcome Score (time frame: Pre-operative). The study lists 24 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in